Vagus Nerve Stimulator Market Size, Trends & Growth Opportunity By Device Type, By Therapy Indication, By Technology Platform, By Customer Type, By Region and Forecast Till 2030

Report ID : AMR1006204 | Industries : Healthcare | Published On :September 2026 | Page Count : 239

Request Sample
Ask for Customization

The global vagus nerve stimulator (VNS) devices market covers implantable and non-invasive devices and related systems supplied for vagus nerve stimulation therapy across a range of neurological and psychiatric indications, spanning North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.

A vagus nerve stimulator is a device that delivers electrical stimulation to the vagus nerve, either through a surgically implanted pulse generator and lead system or through a non-invasive, externally applied system, and this report describes the category strictly as a market segment.

It makes no claim about seizure control, depression remission, stroke rehabilitation outcome, migraine or pain relief, anti-inflammatory outcome or any other clinical or comparative-performance outcome for any product or company described on these pages.

Nine segmentation dimensions appear in this report, and the first two describe the device type supplied and the product component it is built around.

Device type spans four categories: implantable VNS systems, non-invasive VNS systems, rechargeable VNS systems and non-rechargeable VNS systems.

The most useful commercial observation about this market is that implantable-versus-non-invasive form factor, not rechargeability alone, is the specification variable that most shapes which device category a given case can be routed to.

Whether a system requires surgical implantation or is applied externally determines which of the four device type categories are even viable before rechargeability is considered.

Product component spans five categories, including pulse generators, leads and electrodes, programming systems, patient monitoring platforms and digital connectivity solutions.

Therapy indication spans seven categories, from drug-resistant epilepsy and treatment-resistant depression through post-stroke rehabilitation, migraine management, chronic pain management and inflammatory disorders to other emerging neuromodulation indications, and patient category spans a further three categories: paediatric, adult and geriatric.

Implant setting covers three categories, including inpatient implantation, outpatient implantation and ambulatory surgical centres, while technology platform spans four categories: traditional open-loop systems, responsive stimulation systems, AI-assisted neuromodulation platforms and remote monitoring enabled systems.

Reimbursement status spans three categories, customer type spans seven categories and procurement model completes the segmentation across a further four categories.

This report covers vagus nerve stimulator devices, both implantable and non-invasive, across drug-resistant epilepsy, treatment-resistant depression, post-stroke rehabilitation, migraine management, chronic pain management, inflammatory disorders and other emerging neuromodulation indications.

It excludes responsive neurostimulation, deep brain stimulation and other non-VNS implantable neurostimulator technologies, and pharmaceutical treatments for any of the covered indications outside this report's device scope.

Buyer intelligence in the full report maps neurologists, neurosurgeons, psychiatry directors and hospital procurement directors across all five covered regions, including sales cycle duration and contract value band detail.

Competitive benchmarking compares manufacturers across estimated market position, installed base, clinical evidence portfolio and seven further metrics without disclosing proprietary competitive positioning data.

Market Size and Growth Forecast (2026 to 2030)

The global vagus nerve stimulator devices market is estimated at approximately USD 1.3 Billion in 2025 and is projected to reach approximately USD 2.5 Billion by 2030, expanding at a compound annual growth rate of roughly 14.0 percent.

The estimate covers implantable and non-invasive vagus nerve stimulator devices and related systems across the therapy indications named above, and excludes responsive neurostimulation, deep brain stimulation and pharmaceutical treatments for any covered indication.

Implantable VNS systems account for the largest device type category by revenue, tied to the established position of drug-resistant epilepsy and treatment-resistant depression indications, while non-invasive VNS systems form the fastest-growing device type category as migraine management and other emerging neuromodulation indications extend candidacy beyond surgical candidates.

Drug-resistant epilepsy accounts for the largest therapy indication category by procedure and prescription volume, and treatment-resistant depression forms a fast-growing indication category as regulatory approvals and clinical trial programmes extend evidence generation.

Pulse generators and leads and electrodes together account for the largest product component category by installed base, reflecting the established position of implantable systems.

Academic medical centres and comprehensive epilepsy centres together represent the largest customer type category by clinical involvement, and psychiatric treatment centres increasingly shape purchasing decisions alongside them.

Traditional open-loop and responsive stimulation systems account for the largest technology platform category among established manufacturers, and AI-assisted neuromodulation platforms form a fast-growing technology category tied to rising digital connectivity adoption.

Fully reimbursed therapies account for the largest reimbursement status category in established markets, while self-pay procedures remain a meaningful share of the mix in markets where reimbursement gaps persist.

North America accounts for the largest regional concentration in this report, and Asia-Pacific forms the fastest-growing region tracked, reflecting the considerable untapped opportunity in geographic expansion identified in the report's own competitive mapping.

The forecast assumes global regulatory approvals, reimbursement pathways and clinical evidence generation across the covered indications continue broadly on recent trends, and a material shift in any of the three would move the trajectory.

MetricValue
Market Size (2025)Approximately USD 1.3 Billion
Forecast Size (2030)Approximately USD 2.5 Billion
CAGR (2025-2030)Approximately 14.0%
Base Year2025
Forecast Period2026-2030 (5-year)
Scope NoteImplantable and non-invasive vagus nerve stimulator devices and related systems across drug-resistant epilepsy, treatment-resistant depression, post-stroke rehabilitation, migraine management, chronic pain management and inflammatory disorders only; excludes responsive neurostimulation, deep brain stimulation and pharmaceutical treatments
Largest Device Type CategoryImplantable VNS systems
Fastest-Growing Device Type CategoryNon-invasive VNS systems
Largest Therapy Indication CategoryDrug-resistant epilepsy
Fastest-Growing Therapy Indication CategoryTreatment-resistant depression
Largest Regional ConcentrationNorth America
Fastest-Growing RegionAsia-Pacific

 

Market Drivers

Regulatory approvals and clinical trial programmes are expanding indication coverage across treatment-resistant depression, post-stroke rehabilitation and migraine management, broadening the pool of patients who become candidates for a VNS therapy pathway.

Reimbursement approvals and rising drug-resistant patient growth, both named buying triggers in this market, are easing purchasing pathways for hospital procurement directors and CFOs evaluating a first VNS programme.

Increasing product launches and partnerships and alliances among neuromodulation providers are extending distribution reach and clinical evidence portfolios across the therapy indications this report tracks.

Rising adoption of AI-assisted neuromodulation platforms and remote monitoring enabled systems is supporting expanded digital connectivity solutions across newly implanted and non-invasive systems alike.

Geographic expansions and acquisitions by established manufacturers are extending access to underpenetrated regions identified in the report's own competitive mapping.

TECHNOLOGY WATCH

AI-assisted neuromodulation and remote monitoring capability is shifting from a differentiating feature to a baseline expectation among comprehensive epilepsy centres and psychiatric treatment centres evaluating a first VNS programme, a pattern reinforced by the pace of product launches and partnerships tracked among this market's strategic developments.

 

Market Restraints

A multi-phase sales cycle running from evaluation through clinical validation, procurement review and contract award extends the commercial cycle for every vendor competing in this market.

Reimbursement gaps identified in the report's competitive mapping mean self-pay procedures remain a meaningful share of the reimbursement status mix in several covered markets.

Capital equipment committee and hospital administration budget ownership structures govern the pace at which a given care setting can add VNS implant or non-invasive programme capacity.

Market risks and mitigation factors named in the market playbook point to adjacent neuromodulation approaches competing for the same indication-specific procedure and prescription volume.

Digital monitoring gaps identified in the report's competitive mapping add friction to the post-implant or post-fitting patient management ecosystem across several therapy indications.

PROCUREMENT INSIGHT

Hospital procurement directors increasingly evaluate a VNS vendor's capital equipment budgeting fit well before a specific implant or fitting case is scheduled, meaning the multi-phase sales cycle documented in this market functions as a genuine adoption barrier rather than a one-time onboarding delay.

 

Market Opportunities

Therapy indication gaps identified in the report's competitive mapping point to indication areas, beyond drug-resistant epilepsy, where vendor coverage remains less established.

Considerable untapped opportunity in geographic expansion reflects regions where installed base and non-invasive adoption remain thin relative to neuromodulation centre of excellence density elsewhere.

Digital monitoring opportunities extend commercial reach beyond the initial implant or device fitting and into the ongoing patient connectivity relationship.

Emerging market opportunities named in the report's competitive mapping point to regions positioned for earlier-stage category development.

Emerging indication expansion and competitive displacement opportunities point toward multi-indication portfolio breadth as a differentiator for manufacturers with both implantable and non-invasive platforms.

VNS Device Types and Product Components

Buyers evaluating vagus nerve stimulator device types increasingly weigh product component breadth alongside device type when narrowing a shortlist, since implantable, non-invasive, rechargeable and non-rechargeable VNS systems are each built from pulse generators, leads and electrodes, programming systems, patient monitoring platforms and digital connectivity solutions in different combinations.

VNS Therapy Indications and Patient Categories

Drug-resistant epilepsy, treatment-resistant depression, post-stroke rehabilitation, migraine management, chronic pain management, inflammatory disorders and other emerging neuromodulation indications are managed across paediatric, adult and geriatric patient categories, and this spread of therapy indications and patient categories shapes which VNS programme a given centre ultimately builds.

VNS Implant Settings and Care Provider Types

Inpatient implantation, outpatient implantation and ambulatory surgical centres host a customer base spanning academic medical centres, neurology specialty hospitals, neurosurgery centres, comprehensive epilepsy centres, psychiatric treatment centres and veterans healthcare systems, and this mix of implant settings and care provider types varies considerably by indication and device type.

VNS Technology Platforms, Reimbursement and Procurement Models

Traditional open-loop, responsive stimulation, AI-assisted and remote monitoring enabled platforms are purchased through fully reimbursed, partially reimbursed and self-pay pathways using direct hospital procurement, group purchasing organisations, government healthcare procurement and integrated delivery networks, and this combination of technology platforms and procurement models often determines which buyers a given manufacturer can realistically reach.

Vagus Nerve Stimulator Market, By Region

This report covers North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa, reflecting where vagus nerve stimulator adoption is concentrated.

North America accounts for the largest regional concentration in this report, covered through the United States and Canada, with neuromodulation centre of excellence density in cities such as Houston, Cleveland and Boston, and established reimbursement pathways underpinning adoption.

Europe represents a steady, established regional concentration, covered through the United Kingdom, Germany, France, Italy, Spain, the Netherlands, Switzerland, Belgium and the Nordic countries, with centre of excellence activity in London and Paris shaping adoption pace.

Asia-Pacific forms the fastest-growing region tracked in this report, covered through Japan, China, Australia, South Korea, India and Singapore, with expanding neuromodulation centre infrastructure in Tokyo and Sydney supporting adoption.

Latin America is covered through Brazil, Mexico, Argentina, Colombia and Chile, with a deeper state-level view of Brazil covering Sao Paulo, Rio de Janeiro, Minas Gerais, Parana, Rio Grande do Sul and Distrito Federal, and centre of excellence activity concentrated around Sao Paulo.

The Middle East and Africa is covered through Saudi Arabia, the United Arab Emirates, South Africa and Israel, an earlier-stage regional concentration relative to the other four regions tracked.

Regional sizing, growth rates and country-level breakdowns are reserved for the full report rather than presented on this page.

REGIONAL OPPORTUNITY

Asia-Pacific's neuromodulation centre infrastructure is expanding from a smaller base than North America or Western Europe, and manufacturers with established distributor-led international expansion capability are positioned to capture a disproportionate share of the region's growth as adoption of both implantable and non-invasive VNS systems accelerates.

 

Leading Companies

LivaNova, NeuroSigma, electroCore, Parasym Health, Soterix Medical, tVNS Technologies, Cerbomed, NEMOS, BioControl Medical, SetPoint Medical, Medtronic, Abbott Neuromodulation, Boston Scientific Neuromodulation, NeuroPace, Synapse Biomedical and Neuromod Devices are covered in the full report. The supplier landscape organised by company type appears in more depth on the leading vagus nerve stimulator manufacturers page.

Beyond This Page

The full report extends well past the segmentation summarised here and into the commercial detail that shapes how vagus nerve stimulator supply is actually won.

Buyer intelligence maps the buyer ecosystem across neurologists, neurosurgeons, psychiatry directors, hospital procurement directors and medical technology committees in full, including sales cycle duration and contract value band detail.

Decision-maker mapping covers vendor selection criteria, budget ownership pathways, certification requirements and typical implantation or fitting programme economics.

Competitive benchmarking compares manufacturers across installed base, clinical evidence portfolio, distribution reach, regulatory approvals and innovation pipeline.

The market playbook covers VNS pricing structure evolution, reimbursement dynamics, regulatory landscape evolution and physician adoption patterns.

Pricing and procurement chapters cover device pricing structures by region, generator and lead replacement economics, procurement lifecycle detail and total cost of ownership assessment.

Go-to-market chapters set out market entry pathways, distributor and channel mapping, hospital engagement models and major neurology congress activity.

Company profiles cover sixteen manufacturers across geographic footprint, product portfolio, regulatory approvals and certifications, and recent developments.

Frequently Asked Questions

The market is estimated at approximately USD 1.3 Billion in 2025 and is projected to reach approximately USD 2.5 Billion by 2030, expanding at a compound annual growth rate of roughly 14.0 percent.

A device that delivers electrical stimulation to the vagus nerve, either through a surgically implanted pulse generator and lead system or through a non-invasive, externally applied system. This report describes the category strictly as a market segment.

Four device type categories are tracked: implantable VNS systems, non-invasive VNS systems, rechargeable VNS systems and non-rechargeable VNS systems.

Seven indication categories are tracked: drug-resistant epilepsy, treatment-resistant depression, post-stroke rehabilitation, migraine management, chronic pain management, inflammatory disorders and other emerging neuromodulation indications.

North America accounts for the largest regional concentration, covered through the United States and Canada, while Asia-Pacific forms the fastest-growing region tracked in this report.

Regulatory approvals and clinical trial programmes expanding indication coverage are the leading driver, broadening the pool of patients who become candidates for a VNS therapy pathway.

An implantable system uses a surgically placed pulse generator and lead system connected to the vagus nerve, while a non-invasive system applies stimulation externally without surgery. Both are named here as device type market categories.

Drug-resistant epilepsy accounts for the largest therapy indication category by procedure and prescription volume, alongside steady demand from treatment-resistant depression.

Neurologists, neurosurgeons and psychiatry directors most commonly lead clinical evaluation, working alongside hospital procurement directors and medical technology committees through direct hospital procurement, group purchasing organisations and integrated delivery network purchasing pathways.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. Vagus Nerve Stimulator Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.3.1. Regulatory Approvals and Clinical Trial Programmes Are Expanding Indication Coverage Across Treatment-Resistant Depression, Post-Stroke Rehabilitation and Migraine Management, Broadening the Pool of Patients Who Become Candidates for a VNS Therapy Pathway.

3.3.2. Reimbursement Approvals and Rising Drug-Resistant Patient Growth, Both Named Buying Triggers in This Market, Are Easing Purchasing Pathways for Hospital Procurement Directors and CFOs Evaluating a First VNS Programme.

3.3.3. Increasing Product Launches and Partnerships and Alliances Among Neuromodulation Providers Are Extending Distribution Reach and Clinical Evidence Portfolios Across the Therapy Indications This Report Tracks.

3.3.4. Rising Adoption of AI-Assisted Neuromodulation Platforms and Remote Monitoring Enabled Systems Is Supporting Expanded Digital Connectivity Solutions Across Newly Implanted and Non-Invasive Systems Alike.

3.3.5. Geographic Expansions and Acquisitions by Established Manufacturers Are Extending Access to Underpenetrated Regions Identified in the Report's Competitive Mapping.

3.4. Restraints

3.4.1. A Multi-Phase Sales Cycle Running from Evaluation Through Clinical Validation, Procurement Review and Contract Award Extends the Commercial Cycle for Every Vendor Competing in This Market.

3.4.2. Reimbursement Gaps Identified in the Report's Competitive Mapping Mean Self-Pay Procedures Remain a Meaningful Share of the Reimbursement Status Mix in Several Covered Markets.

3.4.3. Capital Equipment Committee and Hospital Administration Budget Ownership Structures Govern the Pace at Which a Given Care Setting Can Add VNS Implant or Non-Invasive Programme Capacity.

3.4.4. Market Risks and Mitigation Factors Named in the Market Playbook Point to Adjacent Neuromodulation Approaches Competing for the Same Indication-Specific Procedure and Prescription Volume.

3.4.5. Digital Monitoring Gaps Identified in the Report's Competitive Mapping Add Friction to the Post-Implant or Post-Fitting Patient Management Ecosystem Across Several Therapy Indications.

3.5. Opportunities

3.5.1. Therapy Indication Gaps Identified in the Report's Competitive Mapping Point to Indication Areas, Beyond Drug-Resistant Epilepsy, Where Vendor Coverage Remains Less Established.

3.5.2. Considerable Untapped Opportunity in Geographic Expansion Reflects Regions Where Installed Base and Non-Invasive Adoption Remain Thin Relative to Neuromodulation Centre of Excellence Density Elsewhere.

3.5.3. Digital Monitoring Opportunities Extend Commercial Reach Beyond the Initial Implant or Device Fitting and into the Ongoing Patient Connectivity Relationship.

3.5.4. Emerging Market Opportunities Named in the Report's Competitive Mapping Point to Regions Positioned for Earlier-Stage Category Development.

3.5.5. Emerging Indication Expansion and Competitive Displacement Opportunities, Both Named in the Source's Own Strategic Relevance Mapping, Point Toward Multi-Indication Portfolio Breadth as a Differentiator.

3.6. Porter's Five Forces Model

3.7. Value Chain Analysis

4. Device Type

4.1. Implantable VNS Systems

4.2. Non-Invasive VNS Systems

4.3. Rechargeable VNS Systems

4.4. Non-Rechargeable VNS Systems

5. Product Component

5.1. Pulse Generators

5.2. Leads and Electrodes

5.3. Programming Systems

5.4. Patient Monitoring Platforms

5.5. Digital Connectivity Solutions

6. Therapy Indication

6.1. Drug-Resistant Epilepsy

6.2. Treatment-Resistant Depression

6.3. Post-Stroke Rehabilitation

6.4. Migraine Management

6.5. Chronic Pain Management

6.6. Inflammatory Disorders

6.7. Other Emerging Neuromodulation Indications

7. Patient Category

7.1. Paediatric

7.2. Adult

7.3. Geriatric

8. Implant Setting

8.1. Inpatient Implantation

8.2. Outpatient Implantation

8.3. Ambulatory Surgical Centres

9. Technology Platform

9.1. Traditional Open-Loop Systems

9.2. Responsive Stimulation Systems

9.3. AI-Assisted Neuromodulation Platforms

9.4. Remote Monitoring Enabled Systems

10. Reimbursement Status

10.1. Fully Reimbursed Therapies

10.2. Partially Reimbursed Therapies

10.3. Self-Pay Procedures

11. Customer Type

11.1. Academic Medical Centres

11.2. Neurology Specialty Hospitals

11.3. Neurosurgery Centres

11.4. Comprehensive Epilepsy Centres

11.5. Psychiatric Treatment Centres

11.6. Ambulatory Surgical Centres

11.7. Veterans Healthcare Systems

12. Procurement Model

12.1. Direct Hospital Procurement

12.2. Group Purchasing Organisations (GPOs)

12.3. Government Healthcare Procurement

12.4. Integrated Delivery Networks (IDNs)

13. Buyer Intelligence and Demand Landscape

13.1. Buyer Segmentation

13.1.1. Public Hospitals

13.1.2. Private Hospitals

13.1.3. University Medical Centres

13.1.4. Specialty Neurology Networks

13.1.5. Neurosurgical Centres

13.2. Buyer Industries

13.2.1. Neurology

13.2.2. Neurosurgery

13.2.3. Psychiatry

13.2.4. Rehabilitation Medicine

13.2.5. Academic Research

13.3. Buyer Company Types

13.3.1. Public Healthcare Systems

13.3.2. Private Hospital Groups

13.3.3. Teaching Hospitals

13.3.4. Specialty Care Networks

13.4. Country-Wise Buyer Mapping

13.4.1. Top Epilepsy Centres

13.4.2. Neuromodulation Centres

13.4.3. Psychiatric Treatment Networks

13.4.4. Academic Research Institutions

13.5. Regional Demand Clusters

13.5.1. North America

13.5.2. Western Europe

13.5.3. Japan

13.5.4. Australia

13.5.5. Brazil

13.5.6. GCC Countries

13.6. Buyer Scale Classification

13.6.1. National Healthcare Systems

13.6.2. Large Hospital Networks

13.6.3. Regional Centres

13.6.4. Independent Specialty Centres

13.7. Procurement Models

13.7.1. Direct Tender Procurement

13.7.2. Framework Agreements

13.7.3. Multi-Year Device Contracts

13.7.4. Outcome-Based Purchasing

13.8. Buying Triggers

13.8.1. Drug-Resistant Patient Growth

13.8.2. Clinical Guideline Updates

13.8.3. Reimbursement Approvals

13.8.4. Competitive Therapy Limitations

13.9. Decision-Maker Roles

13.9.1. Neurologists

13.9.2. Neurosurgeons

13.9.3. Psychiatry Directors

13.9.4. Hospital Procurement Directors

13.9.5. CFOs

13.9.6. Medical Technology Committees

13.10. Budget Ownership

13.10.1. Clinical Departments

13.10.2. Capital Equipment Committees

13.10.3. Hospital Administration

13.10.4. Government Health Authorities

13.11. Vendor Selection Criteria

13.11.1. Clinical Outcomes

13.11.2. Safety Profile

13.11.3. Long-Term Efficacy

13.11.4. Physician Support

13.11.5. Reimbursement Support

13.11.6. Service Capabilities

13.12. Contract Value Bands

13.12.1. Pilot Programmes

13.12.2. Single-Centre Contracts

13.12.3. Regional Network Contracts

13.12.4. National Framework Agreements

13.13. Sales Cycle Analysis

13.13.1. Evaluation Phase

13.13.2. Clinical Validation Phase

13.13.3. Procurement Review

13.13.4. Contract Award

13.13.5. Post-Implementation Assessment

13.14. Strategic Relevance for LivaNova

13.14.1. Hospital Penetration Opportunities

13.14.2. Competitive Displacement Opportunities

13.14.3. Emerging Indication Expansion

13.14.4. Regional Growth Prioritisation

14. By Region

14.1. Global

15. Global Market Analysis and Forecast (2026–2030)

15.1. Introduction

15.2. Market Share Analysis

15.3. Market Size and Forecast

15.4. Market Size and Forecast, By Geography

15.4.1. North America

15.4.1.1. Market Share Analysis

15.4.1.2. Market Size and Forecast

15.4.1.3. By Product

15.4.1.4. By Technology

15.4.1.5. By Application

15.4.1.6. By Customer

15.4.1.7. United States

15.4.1.7.1. Market Share Analysis

15.4.1.7.2. Market Size and Forecast

15.4.1.7.3. By Product

15.4.1.7.4. By Technology

15.4.1.7.5. By Application

15.4.1.7.6. By Customer

15.4.1.8. Canada

15.4.1.8.1. Market Share Analysis

15.4.1.8.2. Market Size and Forecast

15.4.1.8.3. By Product

15.4.1.8.4. By Technology

15.4.1.8.5. By Application

15.4.1.8.6. By Customer

15.4.2. Europe

15.4.2.1. Market Share Analysis

15.4.2.2. Market Size and Forecast

15.4.2.3. By Product

15.4.2.4. By Technology

15.4.2.5. By Application

15.4.2.6. By Customer

15.4.2.7. United Kingdom

15.4.2.7.1. Market Share Analysis

15.4.2.7.2. Market Size and Forecast

15.4.2.7.3. By Product

15.4.2.7.4. By Technology

15.4.2.7.5. By Application

15.4.2.7.6. By Customer

15.4.2.8. Germany

15.4.2.8.1. Market Share Analysis

15.4.2.8.2. Market Size and Forecast

15.4.2.8.3. By Product

15.4.2.8.4. By Technology

15.4.2.8.5. By Application

15.4.2.8.6. By Customer

15.4.2.9. France

15.4.2.9.1. Market Share Analysis

15.4.2.9.2. Market Size and Forecast

15.4.2.9.3. By Product

15.4.2.9.4. By Technology

15.4.2.9.5. By Application

15.4.2.9.6. By Customer

15.4.2.10. Italy

15.4.2.10.1. Market Share Analysis

15.4.2.10.2. Market Size and Forecast

15.4.2.10.3. By Product

15.4.2.10.4. By Technology

15.4.2.10.5. By Application

15.4.2.10.6. By Customer

15.4.2.11. Spain

15.4.2.11.1. Market Share Analysis

15.4.2.11.2. Market Size and Forecast

15.4.2.11.3. By Product

15.4.2.11.4. By Technology

15.4.2.11.5. By Application

15.4.2.11.6. By Customer

15.4.2.12. Netherlands

15.4.2.12.1. Market Share Analysis

15.4.2.12.2. Market Size and Forecast

15.4.2.12.3. By Product

15.4.2.12.4. By Technology

15.4.2.12.5. By Application

15.4.2.12.6. By Customer

15.4.2.13. Switzerland

15.4.2.13.1. Market Share Analysis

15.4.2.13.2. Market Size and Forecast

15.4.2.13.3. By Product

15.4.2.13.4. By Technology

15.4.2.13.5. By Application

15.4.2.13.6. By Customer

15.4.2.14. Belgium

15.4.2.14.1. Market Share Analysis

15.4.2.14.2. Market Size and Forecast

15.4.2.14.3. By Product

15.4.2.14.4. By Technology

15.4.2.14.5. By Application

15.4.2.14.6. By Customer

15.4.2.15. Nordic Countries

15.4.2.15.1. Market Share Analysis

15.4.2.15.2. Market Size and Forecast

15.4.2.15.3. By Product

15.4.2.15.4. By Technology

15.4.2.15.5. By Application

15.4.2.15.6. By Customer

15.4.3. Asia-Pacific

15.4.3.1. Market Share Analysis

15.4.3.2. Market Size and Forecast

15.4.3.3. By Product

15.4.3.4. By Technology

15.4.3.5. By Application

15.4.3.6. By Customer

15.4.3.7. Japan

15.4.3.7.1. Market Share Analysis

15.4.3.7.2. Market Size and Forecast

15.4.3.7.3. By Product

15.4.3.7.4. By Technology

15.4.3.7.5. By Application

15.4.3.7.6. By Customer

15.4.3.8. China

15.4.3.8.1. Market Share Analysis

15.4.3.8.2. Market Size and Forecast

15.4.3.8.3. By Product

15.4.3.8.4. By Technology

15.4.3.8.5. By Application

15.4.3.8.6. By Customer

15.4.3.9. Australia

15.4.3.9.1. Market Share Analysis

15.4.3.9.2. Market Size and Forecast

15.4.3.9.3. By Product

15.4.3.9.4. By Technology

15.4.3.9.5. By Application

15.4.3.9.6. By Customer

15.4.3.10. South Korea

15.4.3.10.1. Market Share Analysis

15.4.3.10.2. Market Size and Forecast

15.4.3.10.3. By Product

15.4.3.10.4. By Technology

15.4.3.10.5. By Application

15.4.3.10.6. By Customer

15.4.3.11. India

15.4.3.11.1. Market Share Analysis

15.4.3.11.2. Market Size and Forecast

15.4.3.11.3. By Product

15.4.3.11.4. By Technology

15.4.3.11.5. By Application

15.4.3.11.6. By Customer

15.4.3.12. Singapore

15.4.3.12.1. Market Share Analysis

15.4.3.12.2. Market Size and Forecast

15.4.3.12.3. By Product

15.4.3.12.4. By Technology

15.4.3.12.5. By Application

15.4.3.12.6. By Customer

15.4.4. Latin America

15.4.4.1. Market Share Analysis

15.4.4.2. Market Size and Forecast

15.4.4.3. By Product

15.4.4.4. By Technology

15.4.4.5. By Application

15.4.4.6. By Customer

15.4.4.7. Brazil

15.4.4.7.1. Market Share Analysis

15.4.4.7.2. Market Size and Forecast

15.4.4.7.3. By Product

15.4.4.7.4. By Technology

15.4.4.7.5. By Application

15.4.4.7.6. By Customer

15.4.4.7.7. Sao Paulo

15.4.4.7.7.1. Market Share Analysis

15.4.4.7.7.2. Market Size and Forecast

15.4.4.7.7.3. By Product

15.4.4.7.7.4. By Technology

15.4.4.7.7.5. By Application

15.4.4.7.7.6. By Customer

15.4.4.7.8. Rio De Janeiro

15.4.4.7.8.1. Market Share Analysis

15.4.4.7.8.2. Market Size and Forecast

15.4.4.7.8.3. By Product

15.4.4.7.8.4. By Technology

15.4.4.7.8.5. By Application

15.4.4.7.8.6. By Customer

15.4.4.7.9. Minas Gerais

15.4.4.7.9.1. Market Share Analysis

15.4.4.7.9.2. Market Size and Forecast

15.4.4.7.9.3. By Product

15.4.4.7.9.4. By Technology

15.4.4.7.9.5. By Application

15.4.4.7.9.6. By Customer

15.4.4.7.10. Parana

15.4.4.7.10.1. Market Share Analysis

15.4.4.7.10.2. Market Size and Forecast

15.4.4.7.10.3. By Product

15.4.4.7.10.4. By Technology

15.4.4.7.10.5. By Application

15.4.4.7.10.6. By Customer

15.4.4.7.11. Rio Grande Do Sul

15.4.4.7.11.1. Market Share Analysis

15.4.4.7.11.2. Market Size and Forecast

15.4.4.7.11.3. By Product

15.4.4.7.11.4. By Technology

15.4.4.7.11.5. By Application

15.4.4.7.11.6. By Customer

15.4.4.7.12. Distrito Federal

15.4.4.7.12.1. Market Share Analysis

15.4.4.7.12.2. Market Size and Forecast

15.4.4.7.12.3. By Product

15.4.4.7.12.4. By Technology

15.4.4.7.12.5. By Application

15.4.4.7.12.6. By Customer

15.4.4.8. Mexico

15.4.4.8.1. Market Share Analysis

15.4.4.8.2. Market Size and Forecast

15.4.4.8.3. By Product

15.4.4.8.4. By Technology

15.4.4.8.5. By Application

15.4.4.8.6. By Customer

15.4.4.9. Argentina

15.4.4.9.1. Market Share Analysis

15.4.4.9.2. Market Size and Forecast

15.4.4.9.3. By Product

15.4.4.9.4. By Technology

15.4.4.9.5. By Application

15.4.4.9.6. By Customer

15.4.4.10. Colombia

15.4.4.10.1. Market Share Analysis

15.4.4.10.2. Market Size and Forecast

15.4.4.10.3. By Product

15.4.4.10.4. By Technology

15.4.4.10.5. By Application

15.4.4.10.6. By Customer

15.4.4.11. Chile

15.4.4.11.1. Market Share Analysis

15.4.4.11.2. Market Size and Forecast

15.4.4.11.3. By Product

15.4.4.11.4. By Technology

15.4.4.11.5. By Application

15.4.4.11.6. By Customer

15.4.5. Middle East and Africa

15.4.5.1. Market Share Analysis

15.4.5.2. Market Size and Forecast

15.4.5.3. By Product

15.4.5.4. By Technology

15.4.5.5. By Application

15.4.5.6. By Customer

15.4.5.7. Saudi Arabia

15.4.5.7.1. Market Share Analysis

15.4.5.7.2. Market Size and Forecast

15.4.5.7.3. By Product

15.4.5.7.4. By Technology

15.4.5.7.5. By Application

15.4.5.7.6. By Customer

15.4.5.8. United Arab Emirates

15.4.5.8.1. Market Share Analysis

15.4.5.8.2. Market Size and Forecast

15.4.5.8.3. By Product

15.4.5.8.4. By Technology

15.4.5.8.5. By Application

15.4.5.8.6. By Customer

15.4.5.9. South Africa

15.4.5.9.1. Market Share Analysis

15.4.5.9.2. Market Size and Forecast

15.4.5.9.3. By Product

15.4.5.9.4. By Technology

15.4.5.9.5. By Application

15.4.5.9.6. By Customer

15.4.5.10. Israel

15.4.5.10.1. Market Share Analysis

15.4.5.10.2. Market Size and Forecast

15.4.5.10.3. By Product

15.4.5.10.4. By Technology

15.4.5.10.5. By Application

15.4.5.10.6. By Customer

15.5. Qualitative Market Insights

15.5.1. Neuromodulation Centres of Excellence and Adoption Hubs Named in the Source Cut Across Regions Rather Than Sitting Inside a Single Country Tier: Houston, Cleveland and Boston in the United States, London and Paris in Europe, Milan in Italy, Sao Paulo in Brazil, Tokyo in Japan and Sydney in Australia.

16. Competition Analysis

16.1. Market Positioning Overview

16.1.1. Global Market Leaders

16.1.2. Implantable VNS Specialists

16.1.3. Non-Invasive Neuromodulation Providers

16.1.4. Psychiatric Neuromodulation Innovators

16.1.5. Emerging Digital Neuromodulation Companies

16.2. Competitive Benchmarking Metrics

16.2.1. Estimated Market Position

16.2.2. Installed Base

16.2.3. Therapy Adoption

16.2.4. Pricing Strategy

16.2.5. Clinical Evidence Portfolio

16.2.6. Distribution Reach

16.2.7. Regulatory Approvals

16.2.8. Reimbursement Coverage

16.2.9. Service Infrastructure

16.2.10. Innovation Pipeline

16.3. Strategic Moves

16.3.1. Product Launches

16.3.2. Regulatory Approvals

16.3.3. Clinical Trial Programmes

16.3.4. Partnerships and Alliances

16.3.5. Acquisitions

16.3.6. Geographic Expansions

16.3.7. R&D Investments

16.4. Competitive Mapping & Gaps

16.4.1. Therapy Indication Gaps

16.4.2. Considerable Untapped Opportunity in Geographic Expansion

16.4.3. Reimbursement Gaps

16.4.4. Digital Monitoring Opportunities

16.4.5. Emerging Market Opportunities

17. Company Profiles

17.1. LivaNova

17.1.1. Company Overview

17.1.2. Headquarters, Ownership and Founding Year

17.1.3. Workforce Estimate

17.1.4. Geographic Footprint

17.1.5. Product Portfolio

17.1.6. Therapy Focus

17.1.7. Target Customer Segments

17.1.8. Distribution Strategy

17.1.9. Key Financials

17.1.10. Regulatory Approvals

17.1.11. Certifications

17.1.12. Partnerships and Alliances

17.1.13. Clinical Evidence Portfolio

17.1.14. R&D Activities

17.1.15. Recent Developments

17.1.16. SWOT Snapshot

17.2. NeuroSigma

17.2.1. Company Overview

17.2.2. Headquarters, Ownership and Founding Year

17.2.3. Workforce Estimate

17.2.4. Geographic Footprint

17.2.5. Product Portfolio

17.2.6. Therapy Focus

17.2.7. Target Customer Segments

17.2.8. Distribution Strategy

17.2.9. Key Financials

17.2.10. Regulatory Approvals

17.2.11. Certifications

17.2.12. Partnerships and Alliances

17.2.13. Clinical Evidence Portfolio

17.2.14. R&D Activities

17.2.15. Recent Developments

17.2.16. SWOT Snapshot

17.3. electroCore

17.3.1. Company Overview

17.3.2. Headquarters, Ownership and Founding Year

17.3.3. Workforce Estimate

17.3.4. Geographic Footprint

17.3.5. Product Portfolio

17.3.6. Therapy Focus

17.3.7. Target Customer Segments

17.3.8. Distribution Strategy

17.3.9. Key Financials

17.3.10. Regulatory Approvals

17.3.11. Certifications

17.3.12. Partnerships and Alliances

17.3.13. Clinical Evidence Portfolio

17.3.14. R&D Activities

17.3.15. Recent Developments

17.3.16. SWOT Snapshot

17.4. Parasym Health

17.4.1. Company Overview

17.4.2. Headquarters, Ownership and Founding Year

17.4.3. Workforce Estimate

17.4.4. Geographic Footprint

17.4.5. Product Portfolio

17.4.6. Therapy Focus

17.4.7. Target Customer Segments

17.4.8. Distribution Strategy

17.4.9. Key Financials

17.4.10. Regulatory Approvals

17.4.11. Certifications

17.4.12. Partnerships and Alliances

17.4.13. Clinical Evidence Portfolio

17.4.14. R&D Activities

17.4.15. Recent Developments

17.4.16. SWOT Snapshot

17.5. Soterix Medical

17.5.1. Company Overview

17.5.2. Headquarters, Ownership and Founding Year

17.5.3. Workforce Estimate

17.5.4. Geographic Footprint

17.5.5. Product Portfolio

17.5.6. Therapy Focus

17.5.7. Target Customer Segments

17.5.8. Distribution Strategy

17.5.9. Key Financials

17.5.10. Regulatory Approvals

17.5.11. Certifications

17.5.12. Partnerships and Alliances

17.5.13. Clinical Evidence Portfolio

17.5.14. R&D Activities

17.5.15. Recent Developments

17.5.16. SWOT Snapshot

17.6. tVNS Technologies

17.6.1. Company Overview

17.6.2. Headquarters, Ownership and Founding Year

17.6.3. Workforce Estimate

17.6.4. Geographic Footprint

17.6.5. Product Portfolio

17.6.6. Therapy Focus

17.6.7. Target Customer Segments

17.6.8. Distribution Strategy

17.6.9. Key Financials

17.6.10. Regulatory Approvals

17.6.11. Certifications

17.6.12. Partnerships and Alliances

17.6.13. Clinical Evidence Portfolio

17.6.14. R&D Activities

17.6.15. Recent Developments

17.6.16. SWOT Snapshot

17.7. Cerbomed

17.7.1. Company Overview

17.7.2. Headquarters, Ownership and Founding Year

17.7.3. Workforce Estimate

17.7.4. Geographic Footprint

17.7.5. Product Portfolio

17.7.6. Therapy Focus

17.7.7. Target Customer Segments

17.7.8. Distribution Strategy

17.7.9. Key Financials

17.7.10. Regulatory Approvals

17.7.11. Certifications

17.7.12. Partnerships and Alliances

17.7.13. Clinical Evidence Portfolio

17.7.14. R&D Activities

17.7.15. Recent Developments

17.7.16. SWOT Snapshot

17.8. NEMOS

17.8.1. Company Overview

17.8.2. Headquarters, Ownership and Founding Year

17.8.3. Workforce Estimate

17.8.4. Geographic Footprint

17.8.5. Product Portfolio

17.8.6. Therapy Focus

17.8.7. Target Customer Segments

17.8.8. Distribution Strategy

17.8.9. Key Financials

17.8.10. Regulatory Approvals

17.8.11. Certifications

17.8.12. Partnerships and Alliances

17.8.13. Clinical Evidence Portfolio

17.8.14. R&D Activities

17.8.15. Recent Developments

17.8.16. SWOT Snapshot

17.9. BioControl Medical

17.9.1. Company Overview

17.9.2. Headquarters, Ownership and Founding Year

17.9.3. Workforce Estimate

17.9.4. Geographic Footprint

17.9.5. Product Portfolio

17.9.6. Therapy Focus

17.9.7. Target Customer Segments

17.9.8. Distribution Strategy

17.9.9. Key Financials

17.9.10. Regulatory Approvals

17.9.11. Certifications

17.9.12. Partnerships and Alliances

17.9.13. Clinical Evidence Portfolio

17.9.14. R&D Activities

17.9.15. Recent Developments

17.9.16. SWOT Snapshot

17.10. SetPoint Medical

17.10.1. Company Overview

17.10.2. Headquarters, Ownership and Founding Year

17.10.3. Workforce Estimate

17.10.4. Geographic Footprint

17.10.5. Product Portfolio

17.10.6. Therapy Focus

17.10.7. Target Customer Segments

17.10.8. Distribution Strategy

17.10.9. Key Financials

17.10.10. Regulatory Approvals

17.10.11. Certifications

17.10.12. Partnerships and Alliances

17.10.13. Clinical Evidence Portfolio

17.10.14. R&D Activities

17.10.15. Recent Developments

17.10.16. SWOT Snapshot

17.11. Medtronic

17.11.1. Company Overview

17.11.2. Headquarters, Ownership and Founding Year

17.11.3. Workforce Estimate

17.11.4. Geographic Footprint

17.11.5. Product Portfolio

17.11.6. Therapy Focus

17.11.7. Target Customer Segments

17.11.8. Distribution Strategy

17.11.9. Key Financials

17.11.10. Regulatory Approvals

17.11.11. Certifications

17.11.12. Partnerships and Alliances

17.11.13. Clinical Evidence Portfolio

17.11.14. R&D Activities

17.11.15. Recent Developments

17.11.16. SWOT Snapshot

17.12. Abbott Neuromodulation

17.12.1. Company Overview

17.12.2. Headquarters, Ownership and Founding Year

17.12.3. Workforce Estimate

17.12.4. Geographic Footprint

17.12.5. Product Portfolio

17.12.6. Therapy Focus

17.12.7. Target Customer Segments

17.12.8. Distribution Strategy

17.12.9. Key Financials

17.12.10. Regulatory Approvals

17.12.11. Certifications

17.12.12. Partnerships and Alliances

17.12.13. Clinical Evidence Portfolio

17.12.14. R&D Activities

17.12.15. Recent Developments

17.12.16. SWOT Snapshot

17.13. Boston Scientific Neuromodulation

17.13.1. Company Overview

17.13.2. Headquarters, Ownership and Founding Year

17.13.3. Workforce Estimate

17.13.4. Geographic Footprint

17.13.5. Product Portfolio

17.13.6. Therapy Focus

17.13.7. Target Customer Segments

17.13.8. Distribution Strategy

17.13.9. Key Financials

17.13.10. Regulatory Approvals

17.13.11. Certifications

17.13.12. Partnerships and Alliances

17.13.13. Clinical Evidence Portfolio

17.13.14. R&D Activities

17.13.15. Recent Developments

17.13.16. SWOT Snapshot

17.14. NeuroPace

17.14.1. Company Overview

17.14.2. Headquarters, Ownership and Founding Year

17.14.3. Workforce Estimate

17.14.4. Geographic Footprint

17.14.5. Product Portfolio

17.14.6. Therapy Focus

17.14.7. Target Customer Segments

17.14.8. Distribution Strategy

17.14.9. Key Financials

17.14.10. Regulatory Approvals

17.14.11. Certifications

17.14.12. Partnerships and Alliances

17.14.13. Clinical Evidence Portfolio

17.14.14. R&D Activities

17.14.15. Recent Developments

17.14.16. SWOT Snapshot

17.15. Synapse Biomedical

17.15.1. Company Overview

17.15.2. Headquarters, Ownership and Founding Year

17.15.3. Workforce Estimate

17.15.4. Geographic Footprint

17.15.5. Product Portfolio

17.15.6. Therapy Focus

17.15.7. Target Customer Segments

17.15.8. Distribution Strategy

17.15.9. Key Financials

17.15.10. Regulatory Approvals

17.15.11. Certifications

17.15.12. Partnerships and Alliances

17.15.13. Clinical Evidence Portfolio

17.15.14. R&D Activities

17.15.15. Recent Developments

17.15.16. SWOT Snapshot

17.16. Neuromod Devices

17.16.1. Company Overview

17.16.2. Headquarters, Ownership and Founding Year

17.16.3. Workforce Estimate

17.16.4. Geographic Footprint

17.16.5. Product Portfolio

17.16.6. Therapy Focus

17.16.7. Target Customer Segments

17.16.8. Distribution Strategy

17.16.9. Key Financials

17.16.10. Regulatory Approvals

17.16.11. Certifications

17.16.12. Partnerships and Alliances

17.16.13. Clinical Evidence Portfolio

17.16.14. R&D Activities

17.16.15. Recent Developments

17.16.16. SWOT Snapshot

Frequently Asked Questions

The market is estimated at approximately USD 1.3 Billion in 2025 and is projected to reach approximately USD 2.5 Billion by 2030, expanding at a compound annual growth rate of roughly 14.0 percent.

A device that delivers electrical stimulation to the vagus nerve, either through a surgically implanted pulse generator and lead system or through a non-invasive, externally applied system. This report describes the category strictly as a market segment.

Four device type categories are tracked: implantable VNS systems, non-invasive VNS systems, rechargeable VNS systems and non-rechargeable VNS systems.

Seven indication categories are tracked: drug-resistant epilepsy, treatment-resistant depression, post-stroke rehabilitation, migraine management, chronic pain management, inflammatory disorders and other emerging neuromodulation indications.

North America accounts for the largest regional concentration, covered through the United States and Canada, while Asia-Pacific forms the fastest-growing region tracked in this report.

Regulatory approvals and clinical trial programmes expanding indication coverage are the leading driver, broadening the pool of patients who become candidates for a VNS therapy pathway.

An implantable system uses a surgically placed pulse generator and lead system connected to the vagus nerve, while a non-invasive system applies stimulation externally without surgery. Both are named here as device type market categories.

Drug-resistant epilepsy accounts for the largest therapy indication category by procedure and prescription volume, alongside steady demand from treatment-resistant depression.

Neurologists, neurosurgeons and psychiatry directors most commonly lead clinical evaluation, working alongside hospital procurement directors and medical technology committees through direct hospital procurement, group purchasing organisations and integrated delivery network purchasing pathways.

Inquire Before Buying Request Free Sample Ask For Discount

Vagus nerve stimulator devices separated from the broader neuromodulation devices category

Vagus nerve stimulator devices are frequently reported inside a much larger neuromodulation devices category, which spans spinal cord stimulation, deep brain stimulation, sacral neuromodulation and other technologies not comparable with the activity described here. Published estimates place the total global neuromodulation devices market at approximately USD 6.8 Billion in 2025, rising to approximately USD 10.7 Billion by 2030 at a compound annual growth rate of approximately 9.4 percent. This report's estimate isolates vagus nerve stimulator devices specifically, and the snapshot table states that boundary so the figure is not mistaken for the larger category total.

Derivation from the implantable VNS category's position within neuromodulation

Within the broader neuromodulation devices category, vagus nerve stimulation is a smaller component alongside the larger spinal cord stimulation and deep brain stimulation categories. Cross-referencing that category composition with published estimates placing total implantable vagus nerve stimulation revenue at approximately USD 1.0 to 1.1 Billion in 2025, the majority of it attributable to drug-resistant epilepsy and treatment-resistant depression indications, produces a grounded implantable-VNS baseline for this report.

Adding the non-invasive VNS device category and this report's broader indication scope

This report's scope also includes non-invasive VNS systems, used for migraine management and other emerging neuromodulation indications, which sit outside the implantable-only baseline above. Non-invasive VNS remains a smaller but faster-growing commercial category than implantable VNS as awareness of externally applied stimulation options grows. Combining the implantable baseline with the non-invasive category and this report's broader indication scope produces a combined 2025 base of approximately USD 1.3 Billion for the vagus nerve stimulator devices market as defined in this report.

Forecast basis and its principal sensitivity

The forecast to 2030 of approximately USD 2.5 Billion, at a compound annual growth rate of approximately 14.0 percent, sits above the broader neuromodulation category's 9.4 percent CAGR, reflecting continued indication expansion into treatment-resistant depression, migraine management and inflammatory disorders, rising non-invasive and AI-assisted platform adoption, and the reimbursement broadening identified among this market's own buying triggers. The pace of indication-specific regulatory approvals and reimbursement decisions across the therapy indications this report tracks is the material sensitivity, since implant and fitting volume in this market tracks approval and reimbursement milestones more closely than any single product-level trend.

Frequently Asked Questions

The market is estimated at approximately USD 1.3 Billion in 2025 and is projected to reach approximately USD 2.5 Billion by 2030, expanding at a compound annual growth rate of roughly 14.0 percent.

A device that delivers electrical stimulation to the vagus nerve, either through a surgically implanted pulse generator and lead system or through a non-invasive, externally applied system. This report describes the category strictly as a market segment.

Four device type categories are tracked: implantable VNS systems, non-invasive VNS systems, rechargeable VNS systems and non-rechargeable VNS systems.

Seven indication categories are tracked: drug-resistant epilepsy, treatment-resistant depression, post-stroke rehabilitation, migraine management, chronic pain management, inflammatory disorders and other emerging neuromodulation indications.

North America accounts for the largest regional concentration, covered through the United States and Canada, while Asia-Pacific forms the fastest-growing region tracked in this report.

Regulatory approvals and clinical trial programmes expanding indication coverage are the leading driver, broadening the pool of patients who become candidates for a VNS therapy pathway.

An implantable system uses a surgically placed pulse generator and lead system connected to the vagus nerve, while a non-invasive system applies stimulation externally without surgery. Both are named here as device type market categories.

Drug-resistant epilepsy accounts for the largest therapy indication category by procedure and prescription volume, alongside steady demand from treatment-resistant depression.

Neurologists, neurosurgeons and psychiatry directors most commonly lead clinical evaluation, working alongside hospital procurement directors and medical technology committees through direct hospital procurement, group purchasing organisations and integrated delivery network purchasing pathways.

Inquire Before Buying Request Free Sample Ask For Discount